Lycopene attenuates colistin-induced nephrotoxicity in mice via activation of the Nrf2/HGo-1 pathway

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 579-585

  Dai, Chongshan ^a   Tang, Shusheng ^a   Deng, Sijun ^a   Zhang, Shen ^a   Zhou, Yan ^a   Velkov, Tony ^b   Li, Jian ^b   Xiao, Xilong ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; COLISTIN; CREATININE; GLUTATHIONE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYCOPENE; MESSENGER RNA; POLYMYXIN; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; ANTIINFECTIVE AGENT; CAROTENOID; HMOX1 PROTEIN, MOUSE; MEMBRANE PROTEIN; NFE2L2 PROTEIN, MOUSE; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; KIDNEY PARENCHYMA; LIPID PEROXIDATION; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; UPREGULATION; UREA NITROGEN BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; INBRED MOUSE STRAIN; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD UREA NITROGEN; CAROTENOIDS; COLISTIN; DISEASE MODELS, ANIMAL; FEMALE; HEME OXYGENASE-1; KIDNEY; KIDNEY DISEASES; MEMBRANE PROTEINS; METABOLIC NETWORKS AND PATHWAYS; MICE, INBRED STRAINS; NF-E2-RELATED FACTOR 2; NF-KAPPA B; OXIDATIVE STRESS; PROTECTIVE AGENTS;

EID: 84920127058     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03925-14     Document Type: Article

References (73)

1. Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D. 2013. 10 × ′20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685-1694. http://dx.doi.org/10.1093/cid/cit152.
2. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. 2013. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol 8:711-724. http://dx.doi.org/10.2217/fmb.13.39.
3. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revisited. Clin Microbiol Rev 21:449-465. http://dx.doi.org/10.1128 /CMR.00006-08.
4. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48:1724-1728. http://dx.doi.org/10.1086 /599225.
5. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57:1300-1303. http://dx.doi.org/10.1093/cid/cit453.
6. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. 2012.Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 65:80-87. http://dx.doi.org/10.1016/j .jinf.2012.01.015.
7. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56:4625-4629. http://dx.doi.org/10.1128/AAC.00280-12.
8. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 47:1766-1770. http://dx.doi.org/10 .1128/AAC.47.5.1766-1770.2003.
9. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
10. Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J. 2012. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis 74:213-223. http://dx.doi.org/10 .1016/j.diagmicrobio.2012.07.010.
11. Dai C, Li J, Tang S, Li J, Xiao X. 2014. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother 58:4075-4085. http: //dx.doi.org/10.1128/AAC.00070-14.
12. Yousef JM, Chen G, Hill PA, Nation RL, Li J. 2012. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67:452-459. http: //dx.doi.org/10.1093/jac/dkr483.
13. Azad MA, Finnin BA, Poudyal A, Davis K, Li J, Hill PA, Nation RL, Velkov T, Li J. 24 June 2013. Polymyxin B induces apoptosis in kidney proximal tubular cells. Antimicrob Agents Chemother http://dx.doi.org /10.1128/AAC.02587-12.
14. Pabla N, Dong Z. 2008. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007. http://dx.doi.org/10.1038 /sj.ki.5002786.
15. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. 2011. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79:33-45. http://dx.doi.org /10.1038/ki.2010.337.
16. Ghlissi Z, Hakim A, Sila A, Mnif H, Zeghal K, Rebai T, Bougatef A, Sahnoun Z. 2014. Evaluation of efficacy of natural astaxanthin and vitamin E in prevention of colistin-induced nephrotoxicity in the rat model. Environ Toxicol Pharmacol 37:960-966. http://dx.doi.org/10.1016/j.etap .2014.03.004.
17. Yousef JM, Chen G, Hill PA, Nation RL, Li J. 2011. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55:4044-4049. http://dx.doi.org/10.1128/AAC.00328-11.
18. Ozkan G, Ulusoy S, Orem A, Alkanat M, Mungan S, Yulug E, Yucesan FB. 2013. How does colistin-induced nephropathy develop and can it be treated? Antimicrob Agents Chemother 57:3463-3469. http://dx.doi.org /10.1128/AAC.00343-13.
19. Zoja C, Benigni A, Remuzzi G. 2014. The Nrf2 pathway in the progression of renal disease. Nephrol Dial Transplant 29(Suppl 1):i19-i24. http: //dx.doi.org/10.1093/ndt/gft224.
20. He M, Pan H, Chang RC, So KF, Brecha NC, Pu M. 2014. Activation of the Nrf2/HO-1 antioxidant pathway contributes to the protective effects of Lycium barbarum polysaccharides in the rodent retina after ischemia-reperfusion-induced damage. PLoS One 9:e84800. http://dx.doi.org/10 .1371/journal.pone.0084800.
21. Tan M, Ouyang Y, Jin M, Chen M, Liu P, Chao X, Chen Z, Chen X, Ramassamy C, Gao Y, Pi R. 2013. Downregulation of Nrf2/HO-1 pathway and activation of JNK/c-Jun pathway are involved in homocysteic acid-induced cytotoxicity in HT-22 cells. Toxicol Lett 223:1-8. http://dx .doi.org/10.1016/j.toxlet.2013.08.011.
22. Shelton LM, Park BK, Copple IM. 2013. Role of Nrf2 in protection against acute kidney injury. Kidney Int 84:1090-1095. http://dx.doi.org /10.1038/ki.2013.248.
23. Gozzelino R, Jeney V, Soares MP. 2010. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 50:323-354. http://dx .doi.org/10.1146/annurev.pharmtox.010909.105600.
24. Wu J, Liu X, Fan J, Chen W, Wang J, Zeng Y, Feng X, Yu X, Yang X. 2014. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. Toxicology 318:22-31. http://dx.doi.org/10.1016/j.tox.2014.01.008.
25. Hong YA, Lim JH, Kim MY, Kim EN, Koh ES, Shin SJ, Choi BS, Park CW, Chang YS, Chung S. 2014. Delayed treatment with oleanolic acid attenuates tubulointerstitial fibrosis in chronic cyclosporine nephropathy through Nrf2/HO-1 signaling. J Transl Med 12:50. http://dx.doi.org/10 .1186/1479-5876-12-50.
26. Surh YJ, Na HK. 2008. NF-kappaB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals. Genes Nutr 2:313-317. http://dx.doi.org/10 .1007/s12263-007-0063-0.
27. Li H, Wu S, Shi N, Lian S, Lin W. 2011. Nrf2/HO-1 pathway activation by manganese is associated with reactive oxygen species and ubiquitinproteasome pathway, not MAPKs signaling. J Appl Toxicol 31:690-697. http://dx.doi.org/10.1002/jat.1654.
28. Sahin K, Tuzcu M, Sahin N, Ali S, Kucuk O. 2010. Nrf2/HO-1 signaling pathway may be the prime target for chemoprevention of cisplatininduced nephrotoxicity by lycopene. Food Chem Toxicol 48:2670-2674. http://dx.doi.org/10.1016/j.fct.2010.06.038.
29. Kalayarasan S, Prabhu PN, Sriram N, Manikandan R, Arumugam M, Sudhandiran G. 2009. Diallyl sulfide enhances antioxidants and inhibits inflammation through the activation of Nrf2 against gentamicin-induced nephrotoxicity in Wistar rats. Eur J Pharmacol 606:162-171. http://dx.doi .org/10.1016/j.ejphar.2008.12.055.
30. Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu J, Tang X. 2014. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radic Biol Med 70:68-77. http://dx.doi.org/10.1016/j.freeradbiomed.2014.02.010.
31. Erman F, Tuzcu M, Orhan C, Sahin N, Sahin K. 2014. Effect of lycopene against cisplatin-induced acute renal injury in rats: organic anion and cation transporters evaluation. Biol Trace Elem Res 158:90-95. http://dx .doi.org/10.1007/s12011-014-9914-x.
32. Yue R, Hu H, Yiu KH, Luo T, Zhou Z, Xu L, Zhang S, Li K, Yu Z. 2012. Lycopene protects against hypoxia/reoxygenation-induced apoptosis by preventing mitochondrial dysfunction in primary neonatal mouse cardiomyocytes. PLoS One 7:e50778. http://dx.doi.org/10.1371/journal.pone .0050778.
33. Feng D, Ling WH, Duan RD. 2010. Lycopene suppresses LPS-induced NO and IL-6 production by inhibiting the activation of ERK, p38MAPK, and NF-kappaB in macrophages. Inflamm Res 59:115-121. http://dx.doi .org/10.1007/s00011-009-0077-8.
34. Ateşşahin A, Ceribaşi AO, Yilmaz S. 2007. Lycopene, a carotenoid, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rats. Basic Clin Pharmacol Toxicol 100:371-376. http://dx.doi.org/10 .1111/j.1742-7843.2007.00060.x.
35. Palozza P, Catalano A, Simone R, Cittadini A. 2012. Lycopene as a guardian of redox signalling. Acta Biochim Pol 59:21-25.
36. Dogukan A, Tuzcu M, Agca CA, Gencoglu H, Sahin N, Onderci M, Ozercan IH, Ilhan N, Kucuk O, Sahin K. 2011. A tomato lycopene complex protects the kidney from cisplatin-induced injury via affecting oxidative stress as well as Bax, Bcl-2, and HSPs expression. Nutr Cancer 63:427-434. http://dx.doi.org/10.1080/01635581.2011.535958.
37. Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S. 2006. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 218:164-171. http://dx.doi.org/10.1016/j.tox.2005 .10.015.
38. Karahan I, Atessahin A, Yilmaz S, Ceribasi AO, Sakin F. 2005. Protective effect of lycopene on gentamicin-induced oxidative stress and nephrotoxicity in rats. Toxicology 215:198-204. http://dx.doi.org/10.1016/j .tox.2005.07.007.
39. Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A. 2005. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 212:116-123. http://dx.doi.org/10.1016/j.tox .2005.04.016.
40. Ip BC, Wang XD. 2013. Non-alcoholic steatohepatitis and hepatocellular carcinoma: implications for lycopene intervention. Nutrients 6:124-162. http://dx.doi.org/10.3390/nu6010124.
41. Taye A, Ibrahim BM. 2013. Activation of renal haeme oxygenase-1 alleviates gentamicin-induced acute nephrotoxicity in rats. J Pharm Pharmacol 65:995-1004. http://dx.doi.org/10.1111/jphp.12067.
42. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. http://dx.doi.org /10.1128/AAC.01733-10.
43. Ko H, Jeon M, Choo E, Lee E, Kim T, Jun JB, Gil HW. 2011. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 117:c284-c288. http://dx.doi.org/10.1159 /000320746.
44. Devaraj S, Mathur S, Basu A, Aung HH, Vasu VT, Meyers S, Jialal I. 2008. A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress. J Am Coll Nutr 27:267-273. http://dx.doi.org/10.1080/07315724.2008.10719699.
45. Steinberg FM, Chait A. 1998. Antioxidant vitamin supplementation and lipid peroxidation in smokers. Am J Clin Nutr 68:319-327.
46. Upritchard JE, Sutherland WH, Mann JI. 2000. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 23: 733-738. http://dx.doi.org/10.2337/diacare.23.6.733.
47. Hadley CW, Clinton SK, Schwartz SJ. 2003. The consumption of processed tomato products enhances plasma lycopene concentrations in association with a reduced lipoprotein sensitivity to oxidative damage. J Nutr 133:727-732.
48. Porrini M, Riso P, Brusamolino A, Berti C, Guarnieri S, Visioli F. 2005. Daily intake of a formulated tomato drink affects carotenoid plasma and lymphocyte concentrations and improves cellular antioxidant protection. Br J Nutr 93:93-99. http://dx.doi.org/10.1079/BJN20041315.
49. Visioli F, Riso P, Grande S, Galli C, Porrini M. 2003. Protective activity of tomato products on in vivo markers of lipid oxidation. Eur J Nutr 42:201-206. http://dx.doi.org/10.1007/s00394-003-0415-5.
50. Harms-Ringdahl M, Jenssen D, Haghdoost S. 2012. Tomato juice intake suppressed serum concentration of 8-oxodG after extensive physical activity. Nutr J 11:29. http://dx.doi.org/10.1186/1475-2891-11-29.
51. Sahin K, Sahin N, Kucuk O. 2010. Lycopene and chemotherapy toxicity. Nutr Cancer 62:988-995. http://dx.doi.org/10.1080/01635581.2010.509838.
52. Zhang X, Yang Y, Wang Q. 2014. Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population. Chin Med J (Engl) 127:2143-2146.
53. Morgia G, Cimino S, Favilla V, Russo GI, Squadrito F, Mucciardi G, Masieri L, Minutoli L, Grosso G, Castelli T. 2013. Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. Int Braz J Urol 39:214-221. http://dx.doi.org/10.1590/S1677-5538.IBJU .2013.02.10.23683667.
54. Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP, Jr. 2002. Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 227:881-885.
55. Ozyilmaz E, Ebinc FA, Derici U, Gulbahar O, Goktas G, Elmas C, Oguzulgen IK, Sindel S. 2011. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 37:141-146. http://dx.doi.org/10.1007/s00134-010-2038-7.
56. Liu Y, Dai C, Gao R, Li J. 2013. Ascorbic acid protects against colistin sulfate-induced neurotoxicity in PC12 cells. Toxicol Mech Methods 23: 584-590. http://dx.doi.org/10.3109/15376516.2013.807532.
57. Dai C, Zhang D, Gao R, Zhang X, Li J. 2013. In vitro toxicity of colistin on primary chick cortex neurons and its potential mechanism. Environ Toxicol Pharmacol 36: 659 - 666. http://dx.doi.org/10.1016/j .etap.2013.06.013.
58. Dai C, Li J, Li J. 2013. New insight in colistin induced neurotoxicity with the mitochondrial dysfunction in mice central nervous tissues. Exp Toxicol Pathol 65:941-948. http://dx.doi.org/10.1016/j.etp.2013.01.008.
59. Xu Y, Ruan S, Wu X, Chen H, Zheng K, Fu B. 2013. Autophagy and apoptosis in tubular cells following unilateral ureteral obstruction are associated with mitochondrial oxidative stress. Int J Mol Med 31:628-636. http://dx.doi.org/10.3892/ijmm.2013.1232.
60. Keirstead ND, Wagoner MP, Bentley P, Blais M, Brown C, Cheatham L, Ciaccio P, Dragan Y, Ferguson D, Fikes J, Galvin M, Gupta A, Hale M, Johnson N, Luo W, McGrath F, Pietras M, Price S, Sathe AG, Sasaki JC, Snow D, Walsky RL, Kern G. 2014. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol Sci 137:278-291. http://dx.doi.org/10.1093/toxsci/kft247.
61. Dezoti Fonseca C, Watanabe M, Vattimo Mde F. 2012. Role of heme oxygenase-1 in polymyxin B-induced nephrotoxicity in rats. Antimicrob Agents Chemother 56:5082-5087. http://dx.doi.org/10.1128/AAC.00925-12.
62. Elmore S. 2007. Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495-516. http://dx.doi.org/10.1080/01926230701320337.
63. Coskun PE, Busciglio J. 2012. Oxidative stress and mitochondrial dysfunction in Down's syndrome: relevance to aging and dementia. Curr Gerontol Geriatr Res 2012:383170. http://dx.doi.org/10.1155 /2012/383170.
64. Qu M, Zhou Z, Chen C, Li M, Pei L, Chu F, Yang J, Wang Y, Li L, Liu C, Zhang L, Zhang G, Yu Z, Wang D. 2011. Lycopene protects against trimethyltin-induced neurotoxicity in primary cultured rat hippocampal neurons by inhibiting the mitochondrial apoptotic pathway. Neurochem Int 59:1095-1103. http://dx.doi.org/10.1016/j.neuint.2011.10.005.
65. Kumar P, Kalonia H, Kumar A. 2009. Lycopene modulates nitric oxide pathways against 3-nitropropionic acid-induced neurotoxicity. Life Sci 85:711-718. http://dx.doi.org/10.1016/j.lfs.2009.10.001.
66. Kilic U, Kilic E, Tuzcu Z, Tuzcu M, Ozercan IH, Yilmaz O, Sahin F, Sahin K. 2013. Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutr Metab (Lond) 10:7. http://dx.doi .org/10.1186/1743-7075-10-7.
67. Gounder VK, Arumugam S, Arozal W, Thandavarayan RA, Pitchaimani V, Harima M, Suzuki K, Nomoto M, Watanabe K. 2014. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicin-induced nephrotoxicity in rats. Int Immunopharmacol 18:282-289. http://dx.doi .org/10.1016/j.intimp.2013.11.018.
68. Moon JH, Shin JS, Kim JB, Baek NI, Cho YW, Lee YS, Kay HY, Kim SD, Lee KT. 2013. Protective effects of 6-hydroxy-1-methylindole-3-acetonitrile on cisplatin-induced oxidative nephrotoxicity via Nrf2 inactivation. Food Chem Toxicol 62:159-166. http://dx.doi.org/10.1016/j.fct .2013.08.039.
69. Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, Li CY, Hua KF, Chang WL, Huang JJ, Yang SS, Chen A. 2011. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 51:744-754. http://dx.doi.org/10.1016/j.freeradbiomed .2011.05.016.
70. Lee CK, Park KK, Chung AS, Chung WY. 2012. Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygen-ase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem Toxicol 50:2565-2574. http://dx.doi.org/10.1016/j.fct .2012.01.005.
71. Bellezza I, Tucci A, Galli F, Grottelli S, Mierla AL, Pilolli F, Minelli A. 2012. Inhibition of NF-kappaB nuclear translocation via HO-1 activation underlies alpha-tocopheryl succinate toxicity. J Nutr Biochem 23:1583-1591. http://dx.doi.org/10.1016/j.jnutbio.2011.10.012.
72. Lamkanfi M, Kalai M, Saelens X, Declercq W, Vandenabeele P. 2004. Caspase-1 activates nuclear factor of the kappa-enhancer in B cells independently of its enzymatic activity. J Biol Chem 279:24785-24793. http: //dx.doi.org/10.1074/jbc.M400985200.
73. Simone RE, Russo M, Catalano A, Monego G, Froehlich K, Boehm V, Palozza P. 2011. Lycopene inhibits NF-κB-mediated IL-8 expression and changes redox and PPARgamma signalling in cigarette smoke-stimulated macrophages. PLoS One 6:e19652. http://dx.doi.org/10.1371/journal .pone.0019652.